メリーランド州における急性リンパ性白血病の臨床試験
メリーランド州内の拠点で、急性リンパ性白血病に関する16件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
- National Institutes of Health Clinical Center, Bethesda
被験者募集中
1歳〜25歳 · 全性別 · 2026/10/02更新 · NCT05621291Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT06904066Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT07572136Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- 他10件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
3歳〜65歳 · 全性別 · 2026/09/30更新 · NCT07328503CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
3歳〜39歳 · 全性別 · 2026/09/30更新 · NCT05442515Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06398457The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
3歳〜35歳 · 全性別 · 2026/08/24更新 · NCT02390752Multicenter HomeVENT: Home Values and Experiences Navigation Track
- Johns Hopkins University School of Medicine, Baltimore
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/07/16更新 · NCT06102330Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜120歳 · 全性別 · 2026/07/16更新 · NCT06364423A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Maryland, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/05更新 · NCT04260022Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Johns Hopkins University, Baltimore
- National Cancer Institute, Pediatric Oncology Branch, Bethesda
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。